Comparison of Clinical Backgrounds Between Patients With and Without Primary Endpoints
| Parameter | Patients with cardiac events (n = 30) | Patients without cardiac events (n = 30) | P |
| Mean age ± SD (y) | 53.3 ± 15.0 | 53.4 ± 12.1 | NS |
| Sex (female) | 8 (27) | 11 (37) | NS |
| Coronary risk factors | |||
| Diabetes mellitus | 8 (27) | 4 (13) | NS |
| Hypertension | 7 (23) | 8 (27) | NS |
| Dyslipidemia | 14 (47) | 7 (23) | NS |
| Chronic renal failure | 2 (7) | 3 (10) | NS |
| Underlying cardiac disease | |||
| Prior myocardial infarction | 8 (27) | 3 (10) | |
| Dilated cardiomyopathy | 15 (50) | 7 (23) | |
| Hypertrophic cardiomyopathy | 2 (7) | 5 (17) | NS |
| Arrhythmogenic right ventricular dysplasia | 2 (7) | 4 (13) | |
| Brugada syndrome | 1 (3) | 9 (30) | |
| Idiopathic ventricular arrhythmia | 2 (7) | 2 (7) | |
| NYHA functional class | NS | ||
| I | 15 | 25 | |
| II | 0 | 3 | |
| III | 14 | 0 | |
| IV | 1 | 2 | |
| Mean follow-up period ± SD (mo) | 31 ± 17 | 28 ± 15 | NS |
| ECG (mean ± SD) | |||
| LVEF (%) | 42 ± 18 | 56 ± 15 | 0.002 |
| Left ventricular end-diastolic diameter (mm) | 57 ± 11 | 50 ± 11 | 0.017 |
| BNP (pg/mL) | 209 ± 198 | 101 ± 140 | 0.018 |
| Presenting arrhythmia before ICD implantation | |||
| VF | 6 (20) | 7 (23) | NS |
| Sustained VT | 18 (60) | 8 (27) | 0.02 |
| Nonsustained VT | 6 (20) | 5 (17) | NS |
| Electrophysiologic study | |||
| Inducible VT | 17 (57) | 12 (40) | NS |
| Inducible VF | 16 (53) | 10 (33) | NS |
| Concomitant medication | |||
| Diuretic | 14 (47) | 6 (20) | NS |
| Spironolactone | 15 (50) | 4 (13) | 0.005 |
| Digitalis | 3 (10) | 0 (0) | NS |
| β-blocker | 22 (73) | 11 (37) | 0.011 |
| ACEI/ARB | 19 (63) | 9 (30) | 0.02 |
| Nitrate | 6 (20) | 1 (3) | NS |
NS= not significant; NYHA = New York Heart Association; VF = ventricular fibrillation; VT = ventricular tachyarrhythmias; ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor blocker.
Data in parentheses are percentages.